FDA Type C meeting feedback positions HEALEY ALS Platform Trial as potentially registrational
Neurizon Therapeutics (ASX: NUZ; OTCQB: NUZTF) has received written responses from the US Food and Drug Administration (FDA) to its Type C meeting request for NUZ-001, its investigational treatment for amyotrophic lateral sclerosis (ALS). The company advised of the feedback on 6 October 2026.
The FDA noted that the HEALEY ALS Platform Trial may serve as the single registrational study for a New Drug Application (NDA), subject to meeting the requirement for substantial evidence of effectiveness. Neurizon stated the feedback is consistent with its regulatory strategy and informs preparation of an NDA.
For investors, a single trial potentially serving as the registrational study may reduce the need for a separate pivotal study. Approval still depends on the data.
When big ASX news breaks, our subscribers know first
Pathway to traditional approval
What the FDA said about HEALEY
The FDA noted that the HEALEY ALS Platform Trial, in which NUZ-001 is being evaluated as Regimen I, is a placebo-controlled study designed to assess clinically meaningful endpoints after 36 weeks of treatment. It added that positive results could potentially support a traditional approval pathway.
The possibility of the trial serving as the single registrational study remains subject to substantial evidence of effectiveness, including supporting evidence alongside the study results.
Biomarkers and supporting evidence
The FDA agreed with Neurizon’s approach to measuring plasma neurofilament light chain (NfL), a marker of nerve damage. It outlined the types of evidence that would be needed for NfL to support accelerated approval.
The FDA also noted that a strong scientific rationale would be required if HEALEY’s primary endpoint were not met. Neurizon’s regulatory strategy remains focused on preparing an NDA seeking traditional approval, with biomarker data from HEALEY, including NfL, intended to form part of the supporting evidence.
The scientific rationale behind NUZ-001 centres on TDP-43 aggregation, a pathology present in roughly 97% of ALS cases, which is why preclinical and Phase 1 evidence carries weight in any FDA discussion of supporting data.
Key FDA positions noted in the feedback:
- The HEALEY ALS Platform Trial may serve as the single registrational study for an NDA, subject to substantial evidence of effectiveness.
- Positive results could potentially support a traditional approval pathway.
- NfL measurement was agreed as an approach, with the FDA outlining the evidence needed for NfL to support accelerated approval.
Dr Chris Bremer, Chief Executive Officer
“This feedback gives us valuable guidance as we prepare the evidence package for the NDA for NUZ-001…”
What is a registrational study and why does it matter?
A registrational (pivotal) study is a trial intended to provide the main evidence a regulator reviews when deciding whether to approve a medicine. Traditional approval is generally based on clinical outcomes, while accelerated approval can rely on a biomarker, which is a measurable indicator such as NfL.
If one trial can serve this role, it may save time and capital compared with running an additional study. That outcome is not assured, and approval depends on the data.
NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.
Regimen I status, expanded access and next steps
Regimen I remains on track, with the study fully enrolled and topline results expected in late Q2 CY2027.
The Regimen I trial expansion from 160 to 240 participants kept the same 3:1 randomisation ratio and pulled the topline timeline forward, with funding requirements unchanged.
The NIH-funded NUZ-001 expanded access program is expected to commence in Q1 CY2027. It will provide NUZ-001 to approximately 200 people living with ALS in the US for up to 96 weeks, while generating longer-term safety and biomarker data.
On Fast Track Designation (FTD), the FDA decided in January 2026 not to grant it. The FDA advised that Neurizon may resubmit a request considering the data available, with eligibility determined on review, and the company continues to evaluate the possibility of a resubmission.
| Milestone | Timing | Detail |
|---|---|---|
| Regimen I topline results | Expected late Q2 CY2027 | Study fully enrolled |
| Expanded access program start | Expected Q1 CY2027 | Approximately 200 patients, up to 96 weeks |
| Fast Track Designation | Under evaluation | Resubmission possible |
About the HEALEY ALS Platform Trial:
- Multicentre, double-blind, placebo-controlled adaptive Phase 2/3 trial
- Conducted by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in the US, created in partnership with the Network of Excellence for ALS (NEALS)
- Entry is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS
Dr Bremer said: “With Regimen I fully enrolled and topline results expected in late Q2 CY2027, our focus is on completing the trial and building the clinical and supporting evidence needed for the NDA submission.”
Topline results from Regimen I are the next key catalyst identified in the announcement.
Don’t Miss the Next Healthcare Breakthrough
Join 20,000+ investors getting FREE breaking ASX healthcare news in their inbox within minutes of release, with in-depth analysis already done. Click the “Free Alerts” button at Big News Blast to get market-moving updates the moment they break and stay ahead of the market.